Spyre Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0 | $0 | $886,000 | $2.3M | $18.7M |
| Research and development | $171.7M | $162.8M | $89.5M | $58.6M | $57.1M |
| Operating expenses | $209.6M | $208.6M | $243.2M | $87.1M | $84.4M |
| Operating income | -$209.6M | -$208.6M | -$242.3M | -$84.8M | -$65.6M |
| Pretax income | -$155.2M | -$208.0M | -$338.8M | -$84.0M | -$65.7M |
| Income tax expense | -$15,000 | $51,000 | -$26,000 | -$136,000 | $141,000 |
| Net income | -$155.2M | -$208.0M | -$338.8M | -$83.8M | -$65.8M |
| Balance Sheet | |||||
| Cash and equivalents | $85.7M | $89.4M | $188.9M | $34.9M | $15.1M |
| Current assets | $777.8M | $608.5M | $341.5M | $62.3M | $98.9M |
| Total assets | $777.8M | $608.5M | $341.9M | $71.1M | $109.9M |
| Current liabilities | $58.7M | $54.1M | $32.0M | $14.7M | $20.1M |
| Total liabilities | $62.5M | $90.7M | $73.3M | $20.8M | $26.0M |
| Stockholders' equity | $715.2M | $517.8M | $184.0M | $50.3M | $83.9M |
| Cash Flow Statement | |||||
| Cash from operations | -$169.3M | -$157.4M | -$99.9M | -$80.1M | -$53.7M |
| Depreciation and amortization | $0 | $0 | $744,000 | $1.6M | $1.6M |
| Stock-based compensation | $37.6M | $44.8M | $25.7M | $7.1M | $8.0M |
| Capital expenditure | — | $0 | $0 | $38,000 | $573,000 |
| Free cash flow | — | -$157.4M | -$99.9M | -$80.2M | -$54.3M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Impairments | $0 | $0 | $2.6M | $0 | $0 |
Shares outstanding 86.8M · Free float 64.3%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.